Background

Dipeptidyl peptidase 4 inhibitors (DPP4is) used to treat diabetes have been reported to be associated with an increased risk of bullous pemphigoid (BP). There are no previous reports analyzing the risk of BP in patients who are using other diabetes medications.

Objective

To evaluate the association between diabetes medications other than DPP4i and development of BP.

Methods

We investigated the prevalence of diabetes among patients with BP and the association between the use of diabetes drugs (excluding DPP4i, metformin, and insulin) and BP by analyzing national Finnish registry data for 3397 patients with BP and 12,941 patients with basal cell carcinoma as controls.

Results

Our results show that 19.6% of patients with BP have type 2 diabetes. Use of none of the investigated medications was associated with an increased risk of BP.

Limitations

Because this was a registry-based study, it was not possible to verify the accuracy of the diagnoses. The risk of BP in users of glucagon-like peptide 1 receptor agonists could not be analyzed.

Conclusion

Our study shows that the investigated diabetes drugs are not associated with an increased risk of BP in a Finnish patient database, indicating they can be safely used in this population. Generalization of these results to other populations will require further study.

中文翻译：

---

一项芬兰全国性病例对照研究，除二肽基肽酶4抑制剂以外的口服糖尿病药物与大疱性类天疱疮无关

背景

据报道，用于治疗糖尿病的二肽基肽酶4抑制剂（DPP4is）与大疱性类天疱疮（BP）的风险增加有关。以前没有报告分析正在使用其他糖尿病药物的患者的血压风险。

客观的

评估除DPP4i以外的糖尿病药物与BP发生之间的关联。

方法

我们通过分析3397例BP患者和12,941例基底细胞癌患者的国家芬兰注册表数据，调查了BP患者的糖尿病患病率以及使用糖尿病药物（不包括DPP4i，二甲双胍和胰岛素）与BP之间的关联。

结果

我们的结果表明，有19.6％的BP患者患有2型糖尿病。不使用任何研究药物均会增加BP的风险。

局限性

因为这是基于注册表的研究，所以无法验证诊断的准确性。无法分析胰高血糖素样肽1受体激动剂使用者的BP风险。

结论

我们的研究表明，在芬兰患者数据库中，所研究的糖尿病药物与BP风险增加无关，这表明可以在该人群中安全使用它们。将这些结果推广到其他人群将需要进一步研究。